Floatz logo

Dextromethorphan

Treatment-Refractory Schizophrenia

All India Institute of Medical Sciences, BhubaneswarSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Treatment-Refractory Schizophrenia cohort.

Asset / SponsorPhaseRating
Olanzapine
Dr. Stavroula Rakitzi
Phase 4BB
Risperdal
Dr. Stavroula Rakitzi
Phase 4BB
AMISULPRIDE
University of California, Los Angeles
Phase 4BB
Clozapine
Dr. Stavroula Rakitzi
Phase 4BB
Paliperidone Palmitate 3-Month Formulation
Dr. Stavroula Rakitzi
Phase 4B

View all 23 →

Same molecule, other indications

Dextromethorphan is also rated in:

Pseudobulbar Affect (PBA)Dormant
BBB
Indicative ·
75 / 100
View asset →
stroke disorderDormant
BBB
Indicative ·
73 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →